<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005581</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067266</org_study_id>
    <secondary_id>INRC-GONO-MIG-5</secondary_id>
    <secondary_id>NCI-V99-1562</secondary_id>
    <nct_id>NCT00005581</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer</brief_title>
  <official_title>Epirubicin Plus Paclitaxel Versus Cyclophosphamide, Epirubicin and 5-Fluorouracil as Adjuvant Treatment of Node Positive Breast Cancer Patients: A Controlled Randomized Phase III Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Combining more than one drug may kill more tumor cells. It is not
      yet known which regimen of chemotherapy is more effective for breast cancer.

      PURPOSE: Randomized phase III trial to compare the effectiveness of two regimens of
      combination chemotherapy in treating women who have stage II or stage III breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Compare overall survival and disease free survival after adjuvant chemotherapy
      with epirubicin plus paclitaxel versus cyclophosphamide, epirubicin, and fluorouracil in
      women with stage IIA, IIB, or III breast cancer. II. Compare quality of life in these women
      with these treatment regimens.

      OUTLINE: This is a randomized, multicenter study. Patients are randomized to one of two
      treatment arms within 35 days of surgery. Arm I: Patients receive epirubicin IV followed by
      paclitaxel IV over 3 hours on day 1. Treatment repeats every 21 days for 4 courses. Arm II:
      Patients receive cyclophosphamide IV, epirubicin IV, and fluorouracil IV on day 1. Treatment
      repeats every 21 days for 6 courses. Treatment continues in the absence of disease
      progression or unacceptable toxicity. Patients who are postmenopausal, or premenopausal and
      hormone receptor positive, receive tamoxifen orally once a day for 5 years starting on day 1.
      Patients receive radiotherapy to residual breast after 4 courses of chemotherapy. Quality of
      life is assessed. Patients are followed every 3 months for 3 years, every 6 months for 2
      years, and then annually thereafter.

      PROJECTED ACCRUAL: Approximately 1,000 patients will be accrued for this study over 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2000</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epirubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically confirmed stage IIA, IIB, or III breast cancer
        treated with radical surgery (e.g., mastectomy, quadrantectomy, tumorectomy) and axillary
        lymph node dissection Positive axillary lymph nodes No more than 9 metastatic lymph nodes
        No distant metastases or local or locoregional disease No more than 5 weeks between surgery
        and beginning of study Hormone receptor status: Not specified

        PATIENT CHARACTERISTICS: Age: 70 and under Sex: Female Menopausal status: Not specified
        Performance status: ECOG 0 Life expectancy: Not specified Hematopoietic: WBC at least
        3,000/mm3 Absolute neutrophil count at least 2,000/mm3 Platelet count at least 100,000/mm3
        Hepatic: Transaminases, alkaline phosphatase, and gamma glutamyltransferase no greater than
        1.5 times upper limit of normal Renal: Not specified Cardiovascular: No heart disease that
        precludes use of anthracyclines (i.e., myocardial infarction, uncontrolled angina pectoris,
        uncontrolled arrhythmias, or valve disease) Other: No concurrent pathology that precludes
        use of antineoplastic drugs No mental retardation or psychiatric disease that precludes
        study No other current or prior malignancy within the past 10 years except squamous or
        basal cell skin cancer or carcinoma in situ of the cervix Not pregnant or nursing Fertile
        patients must use effective contraception

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior
        chemotherapy Endocrine therapy: No prior antineoplastic hormonal therapy Radiotherapy: No
        postoperative radiotherapy except to residual breast Surgery: See Disease Characteristics
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Riccardo Rosso, MD</last_name>
    <role>Study Chair</role>
    <affiliation>IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ospedale San Lazzaro</name>
      <address>
        <city>Alba</city>
        <zip>12051</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile di Asti</name>
      <address>
        <city>Asti</city>
        <zip>14100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Oncologico A. Businco</name>
      <address>
        <city>Cagliari</city>
        <zip>09124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santo Spirito Hospital</name>
      <address>
        <city>Casale Monferato</city>
        <zip>1-15033</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Croce</name>
      <address>
        <city>Cuneo</city>
        <zip>12100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Galliera Oncologia</name>
      <address>
        <city>Genoa</city>
        <zip>16128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale per la Ricerca sul Cancro</name>
      <address>
        <city>Genoa</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospendale S. Andrea EST</name>
      <address>
        <city>La Spezia</city>
        <zip>19100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile di Livorno</name>
      <address>
        <city>Livorno</city>
        <zip>57121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carlo Poma Hospital</name>
      <address>
        <city>Mantova</city>
        <zip>46100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda USSL NO 8</name>
      <address>
        <city>Merate</city>
        <zip>22055</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Scientifico H.S. Raffaele</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Croce</name>
      <address>
        <city>Moncalieri</city>
        <zip>10024</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>I.R.C.C.S. Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale St. Santa Chiara</name>
      <address>
        <city>Pisa</city>
        <zip>56100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USL NO 1</name>
      <address>
        <city>San Remo</city>
        <zip>18038</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda U.S.L. 1 - Sassari</name>
      <address>
        <city>Sassari</city>
        <zip>07100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Paolo</name>
      <address>
        <city>Savona</city>
        <zip>17100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osp. Civile USL 18</name>
      <address>
        <city>Sestri Lev.</city>
        <zip>16039</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Sant Anna</name>
      <address>
        <city>Torino</city>
        <zip>10100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Evangelico Valdese</name>
      <address>
        <city>Torino</city>
        <zip>10125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OIRM - Sant Anna</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Mauriziano Umberto I</name>
      <address>
        <city>Torino</city>
        <zip>10128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Maggiore dell' Universita</name>
      <address>
        <city>Trieste</city>
        <zip>34100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Molinette</name>
      <address>
        <city>Turin</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>June 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2000</study_first_submitted>
  <study_first_submitted_qc>May 19, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2004</study_first_posted>
  <last_update_submitted>December 17, 2013</last_update_submitted>
  <last_update_submitted_qc>December 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2013</last_update_posted>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

